posted on 2024-05-03, 08:29authored byLea Weiss, René Classens, Marjolein Schluck, Emilia Grad, Yusuf Dölen, Lieke van der Woude, Dominique van Midden, Lisa Maassen, Kiek Verrijp, Koen van Riessen, Eric van Dinther, Philipp M. Hagemann, Carl G. Figdor, Roel Hammink
The invention of nanosized biomaterials has paved the
way for novel
therapeutics that can manipulate cells on a nanoscale. Nanosized immunofilaments
(IFs) are synthetic filamentous polymers consisting out of polyisocyanopeptides,
which have been recently established as a powerful platform to activate
specific immune cells in vivo such that they raise an antitumor immune
response. However, toxicological effects or immunogenicity toward
the IFs have not yet been investigated. In this study, we evaluated
potential toxic or immunogenic effects in C57BL/6 mice upon intravenous
or subcutaneous injection of nonfunctionalized IFs or immunostimulatory
IFs over 30 days. We here present a detailed analysis of the gross
pathology, hematological parameters, blood biochemistry, histology,
and antibody-response against the IF backbone. Our results demonstrate
that IFs do not induce severe acute or chronic toxicity in mice. After
30 days, we only found elevated IgG-titers in intravenously injected
but not subcutaneously injected mice. In summary, we demonstrate that
IFs can be administered into a living organism without adverse side
effects, thereby establishing the safety of IFs as a therapeutic intervention.